Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis

Inflammatory bowel diseases (IBDs) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical practice; however, it is a costly, time-consuming, invasive, a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-06, Vol.24 (12), p.10159
Main Authors: Baldan-Martin, Montse, Chaparro, María, Gisbert, Javier P
Format: Article
Language:English
Subjects:
Alzheimer's disease
Analysis
Animal models
Big Data
Biomarkers
Clinical medicine
Diagnosis
Endoscopy
Gastrointestinal system
Gastrointestinal tract
Inflammatory bowel disease
Inflammatory bowel diseases
Intestine
Mass spectrometry
Medical research
Medicine, Experimental
Metabolism
Metabolites
Metabolomics
NMR
Nuclear magnetic resonance
Precision medicine
Proteins
Proteomics
Review
Scientific imaging
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammatory bowel diseases (IBDs) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical practice; however, it is a costly, time-consuming, invasive, and uncomfortable procedure for the patients. Therefore, there is an urgent need for sensitive, specific, fast and non-invasive biomarkers for the diagnosis of IBD in medical research. Urine is an excellent biofluid for discovering biomarkers because it is non-invasive to sample. In this review, we aimed to summarize proteomics and metabolomics studies performed in both animal models of IBD and humans that identify urinary biomarkers for IBD diagnosis. Future large-scale multi-omics studies should be conducted in collaboration with clinicians, researchers, and industry to make progress toward the development of sensitive and specific diagnostic biomarkers, thereby making personalized medicine possible.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241210159